Halucenex Life Sciences Inc. targets Australian market following landmark TGA decision

The wholly-owned Creso Pharma subsidiary is currently conducting clinical trials of its synthetic psilocybin formulation as treatment for mental health conditions NEDLANDS, Australia, Feb. 9, 2023 /PRNewswire/ -- Creso Pharma Limited  (ASX:CPH, FRA:1X8) ('Creso Pharma') is pleased to announce its ...